BACKGROUND: Previously, proteomic methods were applied to characterise differentially expressed proteins in microdissected pancreatic ductal adenocarcinoma cells. AIMS: To report that CapG and a related protein, gelsolin, which have established roles in cell motility, are overexpressed in metastatic pancreatic cancer; and to describe their pattern of expression in pancreatic cancer tissue and their effect on cell motility in pancreatic cancer cell lines. METHODS: CapG was identified by mass spectrometry and immunoblotting. CapG and gelsolin expression was assessed by immunohistochemical analysis on a pancreatic cancer tissue microarray and correlated with clinical and pathological parameters. CapG and gelsolin levels were reduced using RNA interface in Suit-2, Panc-1 and MiaPaCa-2 cells. Cell motility was assessed using modified Boyden chamber or wound-healing assays. RESULTS: Multiple isoforms of CapG were detected in pancreatic cancer tissue and cell lines. Immunohistochemical analysis of benign (n = 44 patients) and malignant (n = 69) pancreatic ductal cells showed significantly higher CapG staining intensity in nuclear (p<0.001) and cytoplasmic (p<0.001) compartments of malignant cells. Similarly, gelsolin immunostaining of benign (n = 24 patients) and malignant (n = 68 patients) pancreatic ductal cells showed higher expression in both compartments (both p<0.001). High nuclear CapG was associated with increased tumour size (p = 0.001). High nuclear gelsolin was associated with reduced survival (p = 0.01). Reduction of CapG or gelsolin expression in cell lines by RNAi was accompanied by significantly impaired motility. CONCLUSIONS: Up regulation of these actin-capping proteins in pancreatic cancer and their ability to modulate cell motility in vitro suggest their potentially important role in pancreatic cancer cell motility and consequently dissemination.
BACKGROUND: Previously, proteomic methods were applied to characterise differentially expressed proteins in microdissected pancreatic ductal adenocarcinoma cells. AIMS: To report that CapG and a related protein, gelsolin, which have established roles in cell motility, are overexpressed in metastatic pancreatic cancer; and to describe their pattern of expression in pancreatic cancer tissue and their effect on cell motility in pancreatic cancer cell lines. METHODS: CapG was identified by mass spectrometry and immunoblotting. CapG and gelsolin expression was assessed by immunohistochemical analysis on a pancreatic cancer tissue microarray and correlated with clinical and pathological parameters. CapG and gelsolin levels were reduced using RNA interface in Suit-2, Panc-1 and MiaPaCa-2 cells. Cell motility was assessed using modified Boyden chamber or wound-healing assays. RESULTS: Multiple isoforms of CapG were detected in pancreatic cancer tissue and cell lines. Immunohistochemical analysis of benign (n = 44 patients) and malignant (n = 69) pancreatic ductal cells showed significantly higher CapG staining intensity in nuclear (p<0.001) and cytoplasmic (p<0.001) compartments of malignant cells. Similarly, gelsolin immunostaining of benign (n = 24 patients) and malignant (n = 68 patients) pancreatic ductal cells showed higher expression in both compartments (both p<0.001). High nuclear CapG was associated with increased tumour size (p = 0.001). High nuclear gelsolin was associated with reduced survival (p = 0.01). Reduction of CapG or gelsolin expression in cell lines by RNAi was accompanied by significantly impaired motility. CONCLUSIONS: Up regulation of these actin-capping proteins in pancreatic cancer and their ability to modulate cell motility in vitro suggest their potentially important role in pancreatic cancer cell motility and consequently dissemination.
Authors: Katrien Van Impe; Veerle De Corte; Ludwig Eichinger; Erik Bruyneel; Marc Mareel; Joël Vandekerckhove; Jan Gettemans Journal: J Biol Chem Date: 2003-03-11 Impact factor: 5.157
Authors: Shefal S Parikh; Sally A Litherland; Michael J Clare-Salzler; Wei Li; Paul A Gulig; Frederick S Southwick Journal: Infect Immun Date: 2003-11 Impact factor: 3.441
Authors: Jun Yang; Dongfeng Tan; Harold L Asch; Helen Swede; Gerold Bepler; Joseph Geradts; Kirsten B Moysich Journal: Lung Cancer Date: 2004-10 Impact factor: 5.705
Authors: JianYu Rao; David Seligson; Harri Visapaa; Steve Horvath; Mervi Eeva; Kia Michel; Allan Pantuck; Arie Belldegrun; Aarno Palotie Journal: Cancer Date: 2002-09-15 Impact factor: 6.860
Authors: Ali R Shekouh; Christopher C Thompson; Wendy Prime; Fiona Campbell; Jane Hamlett; C Simon Herrington; Nicholas R Lemoine; Tatjana Crnogorac-Jurcevic; Markus W Buechler; Helmut Friess; John P Neoptolemos; Stephen R Pennington; Eithne Costello Journal: Proteomics Date: 2003-10 Impact factor: 3.984
Authors: Anske Van den Abbeele; Sarah De Clercq; Ariane De Ganck; Veerle De Corte; Berlinda Van Loo; Sameh Hamdy Soror; Vasundara Srinivasan; Jan Steyaert; Joël Vandekerckhove; Jan Gettemans Journal: Cell Mol Life Sci Date: 2010-02-07 Impact factor: 9.261
Authors: T Nedjadi; N Kitteringham; F Campbell; R E Jenkins; B K Park; P Navarro; F Ashcroft; A Tepikin; J P Neoptolemos; E Costello Journal: Br J Cancer Date: 2009-09-01 Impact factor: 7.640